A new study published in the New England Journal of Medicine is confirming Pfizer’s claims of the high levels of effectiveness among adolescents of its COVID-19 vaccine. The study, which looked at 2,260 adolescents between the ages of 12 and 15, observed 100% efficacy in the group, with a favorable safety and side-effect profile. The authors conclude that the Pfizer vaccine produces a greater immune response for adolescents than it does in young adults.

Related News Articles

Headline
Pfizer has submitted a request for the Food and Drug Administration to authorize a 10-microgram booster dose of its bivalent COVID-19 vaccine booster for…
Headline
Health care providers who treat uninsured or underinsured patients with commercially procured bebtelovimab, a COVID-19 monoclonal antibody therapy for…
Headline
Moderna Friday submitted its request that the Food and Drug Administration authorize for emergency use its bivalent COVID-19 vaccine for children and…
Headline
AHA will co-host a Sept. 27 Facebook Live event with AdventHealth on the importance of getting children vaccinated and boosted against COVID-19, which will…
Headline
Insured and uninsured Americans can receive the new bivalent Pfizer or Moderna COVID-19 booster and other COVID-19 vaccines at no cost as long as the federal…
Headline
The Biden Administration will make over 170 million doses of the bivalent COVID-19 vaccine booster available to Americans for free at pharmacies, doctor’s…